[Pilot study of the effect of interferon-alpha on atopic eczema].
In this pilot study 12 patients with moderate to severe atopic eczema were treated with 2 million IU interferon alpha 2a (Roferon A) three times weekly for 8 weeks and followed up for a further 10 weeks: 2 patients showed clear and 9 a slight to moderate reduction of their skin lesions; 1 patient got worse. Pruritus did not decrease and even increased in a few patients, and IgE levels showed no change during and after treatment. All patients noted mild, transient, flu-like symptoms. The efficacy of interferon alpha in the present therapeutic design for the treatment of atopic eczema must thus be classified as only moderate.
Hautklinik und Hautpolinklinik, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin.
J D
JD
Kropp
B
B
Algermissen
S
S
Buck
B M
BM
Czarnetzki
D000328:Adult; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007073:Immunoglobulin E
Pilotstudie zur Wirkung von Interferon alpha beim atopischen Ekzem.